Company News

bioMérieux, a world leader in in vitro diagnostics, celebrates the opening of the company’s Molecular & Genomic Innovation Center. The new 32,000 sq. ft. facility is home to the xPRO™ Program, which has rapidly changed the landscape of food safety diagnostic capabilities by partnering directly with industry leaders to address unmet needs to streamline operational efficiencies and further public health.

bioMérieux is delighted to announce the availability of method validation services for the BIOFIRE^® Mycoplasma test through a new collaboration with Bionique Testing Laboratories, a leading provider of mycoplasma testing services for the life science industry.

On November 11, 2024, the Université de Sherbrooke (UdeS), the Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS) and bioMérieux, a world leader in the field of in vitro diagnostics, announce a three-year agreement to create a Canadian center of excellence dedicated to the fight against antimicrobial resistance and antibiotic stewardship.

Two strategic infrastructures were inaugurated this year on the bioMérieux site of La Balme-les-Grottes (Isère, France): a plastic injection unit in June and a new-generation R&D building in September. The global specialist in in vitro diagnostics is continuing its investments in France, aiming to develop new solutions for public health worldwide.

SpinChip Diagnostics, in which bioMérieux has held an approximate 20% stake since March 2024, has just published results showing the very good performance of its high-sensitivity Point-of-Care (POC) cardiac troponin I (hs-cTnI) assay. This innovative assay, the first of its kind, could significantly improve the diagnosis of acute myocardial infarction.